Pittsburgh Life Sciences Greenhouse

Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania, with an additional office in Canada. Founded in 2014, the company focuses on developing innovative solutions for stroke detection. Its primary product, AlphaStroke, is a portable and non-invasive stroke screening device that assists medical personnel in identifying early signs of both ischemic and hemorrhagic strokes. This device is designed to be low-cost and durable, enabling pre-hospital providers to triage patients effectively and make timely decisions regarding their care. By improving the speed and accuracy of stroke detection, Forest Devices aims to reduce delays in critical treatment for patients experiencing strokes.

Neuro Kinetics, Inc. specializes in eye tracking technology and non-invasive neuro-otologic diagnostic testing tools tailored for audiologists, ENTs, neuro-otologists, neuro-ophthalmologists, and neurologists worldwide. The company’s portfolio includes the I-PORTAL Neuro-Otologic Test Center, a comprehensive system for vestibular and neuro-otologic diagnostics, along with the VEST software for neuro-otologic analysis. Additional products encompass I-Portal Video Nystagmography and I-Portal Video Oculography, which facilitate vestibular diagnostic solutions and eye tracking tests. Neuro Kinetics also supports its clients with maintenance, training, and accessory services. Founded in 1984 and based in Pittsburgh, Pennsylvania, the company aims to enhance the diagnostic capabilities of healthcare professionals and improve patient treatment outcomes. As of September 2019, it operates as a subsidiary of Neurolign Technologies Inc.

Clinical Platform creates short form, video based patient and caregiver information for people that have chronic illnesses and then connects them to clinical trials. The purpose of our business is to improve the outcomes of patients by providing easily accessible and retain-able information on the diagnosis of, treatments for and living with and any chronic disease. It is a fact that better educated patients have improved outcomes.

Clinical Platform creates short form, video based patient and caregiver information for people that have chronic illnesses and then connects them to clinical trials. The purpose of our business is to improve the outcomes of patients by providing easily accessible and retain-able information on the diagnosis of, treatments for and living with and any chronic disease. It is a fact that better educated patients have improved outcomes.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Ariel Precision Medicine is an integrated genomics and digital health company based in Pittsburgh, Pennsylvania, that focuses on providing precision medicine solutions for the diagnosis, monitoring, and treatment of complex chronic diseases. Founded in 2013, the company develops innovative clinical decision support tools designed to simplify personalized treatment, particularly through its flagship product, ArielDx. This cloud-based platform specifically aids in the diagnosis and management of pancreatic disease, enhancing the capabilities of healthcare providers in both emergency and clinical settings. Ariel Precision Medicine aims to improve patient outcomes by leveraging advanced technology and genomic insights in healthcare.

Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania, with an additional office in Canada. Founded in 2014, the company focuses on developing innovative solutions for stroke detection. Its primary product, AlphaStroke, is a portable and non-invasive stroke screening device that assists medical personnel in identifying early signs of both ischemic and hemorrhagic strokes. This device is designed to be low-cost and durable, enabling pre-hospital providers to triage patients effectively and make timely decisions regarding their care. By improving the speed and accuracy of stroke detection, Forest Devices aims to reduce delays in critical treatment for patients experiencing strokes.

Better Body Image, Inc. is a Pittsburgh-based company that specializes in developing a mobile application designed to support individuals in achieving their health and fitness goals. Established in 2013, the company offers a weight loss, wellness, and fitness app that utilizes proprietary technology to generate personalized exercise routines tailored to users' body types, activity levels, and specific objectives. The app, named "View2Lose," incorporates patented artificial intelligence to visualize how users will look upon reaching their desired weight, thereby enhancing motivation. Better Body Image also maintains a body change database aimed at addressing chronic conditions related to waist size and body measurements. In collaboration with AI Ventures, the company seeks to expand its reach globally, targeting one million downloads shortly after the app's launch. The partnership aims to leverage advanced AI capabilities and marketing resources, with an objective of securing a $15 million valuation and raising $2 million in Series A funding to further its mission.

Medrobotics Corporation is a medical robotics company based in Raynham, Massachusetts, specializing in the development and commercialization of the Flex Robotic System. This innovative platform features a steerable and shapeable robotic scope that allows surgeons to navigate complex anatomy through a single, small entry point, addressing hard-to-reach areas that traditional rigid surgical tools cannot access. The Flex Robotic System is complemented by a suite of specialized instruments, including laser holders and various monopolar tools, designed for applications such as transoral robotic surgery and transoral laser microsurgery. Established in 2005 and previously known as Cardiorobotics, Inc., Medrobotics has a strong presence in the European market, focusing on enhancing minimally invasive surgical techniques and improving patient access to advanced surgical procedures.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Cernostics, Inc. is a diagnostics company based in Pittsburgh, Pennsylvania, specializing in cancer diagnostics and prognostics through a tissue systems biology approach. Founded in 2008, Cernostics develops the TissueCypher Barrett’s esophagus assay, which utilizes whole slide digital imaging technology to assess the risk for patients with Barrett’s esophagus, thereby reducing uncertainty in treatment decisions for gastroenterologists. The company's patent-protected TissueCypher platform analyzes whole slide digital images using multiplexed fluorescence, enhancing the accuracy of traditional tissue diagnostics by evaluating tumors as complex systems comprised of multiple cell types. Additionally, Cernostics operates a high-complexity clinical reference laboratory that supports biomarker discovery, validation, and clinical trial efforts, ultimately aiming to improve patient outcomes and reduce healthcare costs. The company has established a strategic collaboration with Deciphex Limited to further its capabilities in spatial biology and AI-driven image analytics.

Complexa, Inc. is a biopharmaceutical company based in Berwyn, Pennsylvania, focused on developing treatments for severe and life-threatening diseases related to fibrosis and inflammation. Established in 2008, the company is advancing its lead compound, CXA-10, an oral nitrated fatty acid aimed at treating focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH). Complexa utilizes proprietary technologies that involve the synthesis of endogenous nitro-fatty acids, which serve as cell-signaling agents regulating key inflammatory pathways. This approach aims to enhance the body's natural mechanisms for resolving and repairing acute and chronic tissue injuries, with a focus on addressing various inflammatory, fibrotic, and central nervous system diseases.

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, dedicated to developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Established in 2007, the company focuses on addressing the underlying cellular damage caused by toxic proteins associated with diseases such as Alzheimer's and dry age-related macular degeneration. Its lead product candidate, CT1812, is an oral drug designed to penetrate the blood-brain barrier and selectively target the S2R complex, aiming to restore normal cellular processes disrupted by these conditions. Cognition Therapeutics combines biological expertise with proprietary assays and medicinal chemistry to create innovative and effective drug candidates for age-related degenerative diseases affecting the central nervous system and retina.

ALung Technologies is a medical device manufacturing company based in Pittsburgh, Pennsylvania, founded in 1997. The company specializes in developing devices for gas exchange to treat acute and chronic respiratory disorders. Its primary product, the Hemolung Respiratory Assist System (RAS), functions as a dialysis-like alternative or supplement to mechanical ventilation, allowing physicians to effectively remove carbon dioxide from the blood without relying solely on the lungs. This technology aims to reduce the need for intubation and invasive ventilation, thereby improving patient outcomes. Additionally, ALung offers the Hattler Catheter, which facilitates the insertion of its gas exchange devices into the central venous bloodstream.

ATRP SOLUTIONS develops and manufactures specialty polymers that meet their needs. It recognizes the polymeric materials for improving the performance of commercial products in the areas of personal care and cosmetics, detergents and surfactants, paints, pigments, coatings, and biocompatible materials. It was founded in 2006 and is headquartered in Pittsburgh, Pennsylvania.

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, dedicated to developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Established in 2007, the company focuses on addressing the underlying cellular damage caused by toxic proteins associated with diseases such as Alzheimer's and dry age-related macular degeneration. Its lead product candidate, CT1812, is an oral drug designed to penetrate the blood-brain barrier and selectively target the S2R complex, aiming to restore normal cellular processes disrupted by these conditions. Cognition Therapeutics combines biological expertise with proprietary assays and medicinal chemistry to create innovative and effective drug candidates for age-related degenerative diseases affecting the central nervous system and retina.

ClearCount Medical Solutions specializes in patient safety solutions for the operating room, focusing on the prevention of medical errors. The company has developed an innovative sponge management system that integrates counting and detection capabilities, enhancing surgical efficiency and patient safety. Utilizing radio frequency identification (RFID) technology, ClearCount's platform enables quick reconciliation of sponge counts during procedures. In cases where a count does not reconcile, the SmartWand™ device assists in locating any missing sponges, further minimizing risks associated with retained surgical items. Through these advancements, ClearCount Medical Solutions aims to improve operational efficiency in surgical environments while ensuring better outcomes for patients.

QuantumOPS is an orthopedic technology company focused on enhancing patient mobility and improving clinical outcomes in surgical environments. It develops equipment such as a shoulder positioning system and a carbon operative arm positioner, along with various accessories for head and body support. These products are designed to help clinicians, orthopedic surgeons, nurses, and anesthesiologists effectively immobilize, stabilize, and position patients of all sizes during shoulder surgeries. The company emphasizes user involvement throughout the design process, ensuring that its innovations meet the specific needs of operating suite professionals. QuantumOPS is committed to agility and responsiveness in addressing market demands.

Complexa, Inc. is a biopharmaceutical company based in Berwyn, Pennsylvania, focused on developing treatments for severe and life-threatening diseases related to fibrosis and inflammation. Established in 2008, the company is advancing its lead compound, CXA-10, an oral nitrated fatty acid aimed at treating focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH). Complexa utilizes proprietary technologies that involve the synthesis of endogenous nitro-fatty acids, which serve as cell-signaling agents regulating key inflammatory pathways. This approach aims to enhance the body's natural mechanisms for resolving and repairing acute and chronic tissue injuries, with a focus on addressing various inflammatory, fibrotic, and central nervous system diseases.

Medrobotics Corporation is a medical robotics company based in Raynham, Massachusetts, specializing in the development and commercialization of the Flex Robotic System. This innovative platform features a steerable and shapeable robotic scope that allows surgeons to navigate complex anatomy through a single, small entry point, addressing hard-to-reach areas that traditional rigid surgical tools cannot access. The Flex Robotic System is complemented by a suite of specialized instruments, including laser holders and various monopolar tools, designed for applications such as transoral robotic surgery and transoral laser microsurgery. Established in 2005 and previously known as Cardiorobotics, Inc., Medrobotics has a strong presence in the European market, focusing on enhancing minimally invasive surgical techniques and improving patient access to advanced surgical procedures.

QuantumOPS is an orthopedic technology company focused on enhancing patient mobility and improving clinical outcomes in surgical environments. It develops equipment such as a shoulder positioning system and a carbon operative arm positioner, along with various accessories for head and body support. These products are designed to help clinicians, orthopedic surgeons, nurses, and anesthesiologists effectively immobilize, stabilize, and position patients of all sizes during shoulder surgeries. The company emphasizes user involvement throughout the design process, ensuring that its innovations meet the specific needs of operating suite professionals. QuantumOPS is committed to agility and responsiveness in addressing market demands.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, dedicated to developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Established in 2007, the company focuses on addressing the underlying cellular damage caused by toxic proteins associated with diseases such as Alzheimer's and dry age-related macular degeneration. Its lead product candidate, CT1812, is an oral drug designed to penetrate the blood-brain barrier and selectively target the S2R complex, aiming to restore normal cellular processes disrupted by these conditions. Cognition Therapeutics combines biological expertise with proprietary assays and medicinal chemistry to create innovative and effective drug candidates for age-related degenerative diseases affecting the central nervous system and retina.

Rinovum Women's Health, Inc. develops medical devices for women. It offers Stork, a medical device that aids in natural fertility and conception in the privacy of home.

STARR Life Sciences Corp. specializes in the development and manufacturing of research equipment for small animal studies, aimed at advancing life sciences. Based in Oakmont, Pennsylvania, the company offers a range of products including the MouseOX Plus pulse oximeter, which measures vital parameters such as heart rate, arterial oxygen saturation, and temperature in mice and rats. Additionally, STARR Life Sciences provides the E-Mitter Telemetry System, enabling continuous monitoring of temperature, activity, and heart rate through implantable telemetry devices and accompanying software. Their product lineup also includes incage running wheels, activity cage systems, and infrared motion sensors, all designed to facilitate non-invasive observation of animal health and behavior. The company's offerings are utilized by researchers, veterinarians, and institutions within the pharmaceutical and academic sectors, reflecting a commitment to supporting medical research through innovative technology.

Applied Computational Technologies is a software development company that specializes in applications for the life sciences, particularly in radiation treatment planning for cancer therapy. With a significant number of cancer diagnoses in the United States, a large portion of patients undergo radiation treatment, highlighting the importance of effective planning tools. The company's flagship product, ProACTive, serves as a dose calculation engine that facilitates adaptive radiotherapy, enhancing the precision and effectiveness of cancer treatment. Through its innovative software solutions, Applied Computational Technologies aims to improve patient outcomes in the challenging field of oncology.

NeuroInterventional Therapeutics, Inc. ("NIT", dba Neurointerventions, Inc.) is a Pittsburgh-based company which designs and manufactures advanced catheter systems used to find, trap, and extract thrombus ("blood clots") in a wide range of cerebral vessels, thereby increasing chances of survival and minimizing disability.

Cernostics, Inc. is a diagnostics company based in Pittsburgh, Pennsylvania, specializing in cancer diagnostics and prognostics through a tissue systems biology approach. Founded in 2008, Cernostics develops the TissueCypher Barrett’s esophagus assay, which utilizes whole slide digital imaging technology to assess the risk for patients with Barrett’s esophagus, thereby reducing uncertainty in treatment decisions for gastroenterologists. The company's patent-protected TissueCypher platform analyzes whole slide digital images using multiplexed fluorescence, enhancing the accuracy of traditional tissue diagnostics by evaluating tumors as complex systems comprised of multiple cell types. Additionally, Cernostics operates a high-complexity clinical reference laboratory that supports biomarker discovery, validation, and clinical trial efforts, ultimately aiming to improve patient outcomes and reduce healthcare costs. The company has established a strategic collaboration with Deciphex Limited to further its capabilities in spatial biology and AI-driven image analytics.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Celsense, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, specializing in the development of innovative magnetic resonance imaging (MRI) agents designed to non-invasively visualize and quantify biological processes at the cellular level. The company's primary offerings include Cell Sense, a MRI cell tracer for monitoring transplanted cells; Gene Sense, a DNA-encoded marker that allows cells to express their own contrast agent; and V-sense, a fluorine-based MRI tracer. Additionally, Celsense provides Voxel Tracker, which facilitates rapid visualization and quantification of MRI-labeled cells. These products are instrumental in regenerative medicine and immunotherapy, allowing for the monitoring of cellular therapeutics, inflammation, cancer metastases, and immune system responses. Founded in 2005, Celsense collaborates with various pharmaceutical and biotechnology organizations to develop applications suitable for human use.

Saladax Biomedical, Inc. is a precision medicine company based in Bethlehem, Pennsylvania, specializing in the development and commercialization of diagnostic blood tests designed to enhance personalized medicine. The company focuses on adherence testing for psychiatrists and chemotherapeutic drug monitoring for oncologists. Its product line, known as MyCare, includes tests such as MyCare Psychiatry, which helps determine the appropriate antipsychotic dosage for patients; MyCare Oncology, which optimizes chemotherapy exposure; and MyCare Neurology, for assessing the effects of neurological drugs. Specific tests include My5-FU, MyPaclitaxel, MyDocetaxel, and MyImatinib, which are used to manage treatment for various cancers and conditions. Saladax markets its products through distributors across the Asia Pacific, European Union, Middle East, and North Africa, as well as through direct sales in select regions. With over 15 years of experience, Saladax aims to provide convenient and cost-effective solutions for therapeutic drug monitoring, enabling physicians to tailor drug dosing to individual patient needs.

Cellumen specializes in cellular systems biology solutions that enhance drug discovery and safety assessment processes for biopharmaceutical researchers. By providing advanced tools for early safety evaluation and discovery toxicology, Cellumen helps organizations improve the accuracy of predicting drug efficacy and safety, ultimately reducing failure rates and development costs. The company's innovative approach addresses the complexities of disease and safety, making it a valuable partner for leading institutions such as the Mayo Clinic, Hamamatsu Photonics K.K., the EPA, FDA, NIH, and prominent pharmaceutical companies. Through its commitment to advancing drug development, Cellumen plays a crucial role in the biopharmaceutical industry.

PeriOptimum provides workflow management solutions and consulting services for the healthcare industry. It offers real-time technology and process management solutions that allow hospitals to improve workflow in the operating room environment and also enables doctors, nurses, and managers to access patient location and clinical information. The company’s solution portfolio includes RealView, a real time workflow management system that allows users to see patient status in real-time and in multiple views; PeriOperative Improvement Evaluation, a process evaluation solution for on-site analysis and off-site data extraction and analysis; Surgical Analytics Services, a service to isolate, analyze, benchmark, and improve indicators; and Surgical Capacity Improvement Program, a process improvement program for the perioperative process. It also provides PeriOp Education Services, a program that enables hospitals to train their new recruits on critical topics and orient them on the hospital's perioperative department; PathFinder, an RFID-based tracking, workflow management, and communications system; and data analytics and workflow reengineering services.

ThermalTherapeutic Systems was founded in June, 2006 by a team of highly respected experts in the field of hyperthermic perfusion technology, medical device manufacturing, molecular diagnostics and technology commercialization.

Medrobotics Corporation is a medical robotics company based in Raynham, Massachusetts, specializing in the development and commercialization of the Flex Robotic System. This innovative platform features a steerable and shapeable robotic scope that allows surgeons to navigate complex anatomy through a single, small entry point, addressing hard-to-reach areas that traditional rigid surgical tools cannot access. The Flex Robotic System is complemented by a suite of specialized instruments, including laser holders and various monopolar tools, designed for applications such as transoral robotic surgery and transoral laser microsurgery. Established in 2005 and previously known as Cardiorobotics, Inc., Medrobotics has a strong presence in the European market, focusing on enhancing minimally invasive surgical techniques and improving patient access to advanced surgical procedures.

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, dedicated to developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Established in 2007, the company focuses on addressing the underlying cellular damage caused by toxic proteins associated with diseases such as Alzheimer's and dry age-related macular degeneration. Its lead product candidate, CT1812, is an oral drug designed to penetrate the blood-brain barrier and selectively target the S2R complex, aiming to restore normal cellular processes disrupted by these conditions. Cognition Therapeutics combines biological expertise with proprietary assays and medicinal chemistry to create innovative and effective drug candidates for age-related degenerative diseases affecting the central nervous system and retina.

Caliber Infosolutions, Inc. is a global company based in Pittsburgh, Pennsylvania, specializing in web-based software applications tailored for regulated industries, particularly in quality management for the pharmaceutical sector. The company offers several key products, including CaliberLIMS, which automates batch, lot, and sample management to ensure compliance with both internal and external specifications. Additionally, Caliber Stability facilitates the pre-registration of stability test protocols and provides detailed statistical analyses of results, along with graphical trend representations. The Caliber Pet-LIMS system delivers customized management information system reports and various testing status reports. Furthermore, Caliber CLAPS offers a controlled label printing solution designed for regulated environments. Caliber Infosolutions also provides validation, implementation, application training, and customer support services. The company serves clients across the biotech, pharmaceutical, oil, and petrochemical industries and has established strategic alliances with notable technology firms. Caliber Infosolutions was incorporated in 2008 and has since developed a reputation for its robust software solutions.

Saladax Biomedical, Inc. is a precision medicine company based in Bethlehem, Pennsylvania, specializing in the development and commercialization of diagnostic blood tests designed to enhance personalized medicine. The company focuses on adherence testing for psychiatrists and chemotherapeutic drug monitoring for oncologists. Its product line, known as MyCare, includes tests such as MyCare Psychiatry, which helps determine the appropriate antipsychotic dosage for patients; MyCare Oncology, which optimizes chemotherapy exposure; and MyCare Neurology, for assessing the effects of neurological drugs. Specific tests include My5-FU, MyPaclitaxel, MyDocetaxel, and MyImatinib, which are used to manage treatment for various cancers and conditions. Saladax markets its products through distributors across the Asia Pacific, European Union, Middle East, and North Africa, as well as through direct sales in select regions. With over 15 years of experience, Saladax aims to provide convenient and cost-effective solutions for therapeutic drug monitoring, enabling physicians to tailor drug dosing to individual patient needs.

Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company based in Pittsburgh, Pennsylvania, specializing in supportive care for cancer survivors who experience hemorrhagic cystitis. Founded in 2005, the company develops innovative products for intravesical therapy, delivering localized treatments directly to the urinary bladder. Its primary product in clinical development is LP-10, a liposomal formulation of tacrolimus aimed at treating hemorrhagic cystitis. Additionally, Lipella focuses on other conditions such as interstitial cystitis, overactive bladder, and superficial bladder cancer, which affect a significant number of patients in the United States. The company also engages in surveillance and imaging for patients with a history of transitional cell carcinoma, alongside offering clinical supplies and research products.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

ParentPlus was formed to alleviate male-factor subfertility by bringing innovative biotechnology to millions of subfertile couples for whom intra-uterine insemination (IUI) might be an appropriate therapy. This therapy, with spousal or donor sperm, is underutilized ― perhaps in part because it is not typically discussed in the popular press.

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, dedicated to developing small-molecule therapeutics for neurodegenerative and neuro-ophthalmic disorders. Established in 2007, the company focuses on addressing the underlying cellular damage caused by toxic proteins associated with diseases such as Alzheimer's and dry age-related macular degeneration. Its lead product candidate, CT1812, is an oral drug designed to penetrate the blood-brain barrier and selectively target the S2R complex, aiming to restore normal cellular processes disrupted by these conditions. Cognition Therapeutics combines biological expertise with proprietary assays and medicinal chemistry to create innovative and effective drug candidates for age-related degenerative diseases affecting the central nervous system and retina.

Crystalplex Corporation, founded in 2001 and based in Pittsburgh, Pennsylvania, specializes in the development of nanocrystals for various applications, including photoluminescence, electroluminescence, and photovoltaics. The company is known for its advanced fluorescent nanoparticle technology, particularly its Sapphire quantum dots, which offer stable crystal designs and flexible polymer matrix morphologies. These products are designed to enhance the performance of high-end consumer electronics, such as LCD TVs and displays, by improving brightness and color quality. Additionally, Crystalplex serves the biomedical research, molecular diagnostic, and pathology markets, providing quicker test results from smaller samples while lowering labor costs and instrumentation expenses. Their proprietary technology meets stringent performance standards while being environmentally responsible, positioning Crystalplex as a leader in the cost-effective manufacturing of robust quantum dots for illumination and solar energy applications.

Applied Isotope Technologies, Inc. specializes in providing measurement solutions for various sectors, including industrial, medical, and academic fields. The company develops and manufactures advanced analytical tools such as direct isotope dilution mass spectrometry (D-IDMS) and direct speciated isotope dilution mass spectrometry (D-SIDMS), which are designed for accurate elemental and molecular analyses. Its product offerings encompass isotopic spikes, reagent kits, and analytical standards specifically tailored for environmental testing, food safety, and biomarker detection. Additionally, Applied Isotope Technologies offers quality assurance certification, training, and technical support services to help laboratories implement precision measurement techniques. Founded in 2003 and based in Pittsburgh, Pennsylvania, the company plays a critical role in environmental toxin detection and other complex analytical challenges.

Separation Design Group, LLC is a research and product development company based in Waynesburg, Pennsylvania, founded in 2003. The company specializes in developing miniature oxygen generators tailored for a variety of applications, including medical, veterinary, and industrial uses. Its offerings encompass portable medical oxygen concentration systems for managing respiratory diseases, oxygen therapy for wound care, personal and sports oxygen solutions, and veterinary oxygen concentrators. Additionally, the company produces oxygen generation modules for ozone generation and hybrid fuel electric aircraft engines. With research facilities located in Pittsburgh, Pennsylvania, and Morgantown, West Virginia, Separation Design Group emphasizes energy-efficient designs that operate at faster cycle times, enhancing the performance and versatility of its oxygen equipment.

InteloMed, Inc. is a medical device manufacturer focused on enhancing cardiovascular monitoring to improve patient outcomes. Founded in 2005 and based in Warrendale, Pennsylvania, the company offers the CVInsight Patient Monitoring & Informatics System. This system captures and analyzes a patient’s pulse waveform using proprietary algorithms, providing noninvasive, real-time insights into cardiovascular stability. It is utilized in various settings including hospitals, outpatient facilities, and during procedures such as hemodialysis and heart failure management. By delivering actionable health information, InteloMed's technology enables clinicians to make informed decisions regarding diagnosis and treatment planning for at-risk patients, thereby improving overall care pathways.

ChemDAQ, Inc. specializes in manufacturing gas detection systems designed to protect personnel from exposure to toxic sterilant gases. The company offers the ChemDAQ sterilant gas monitoring system and the ChemDAQ data acquisition module, which enables continuous monitoring, display, and documentation of sterilant gas levels. Founded in 1996 and based in Pittsburgh, Pennsylvania, ChemDAQ serves a variety of sectors, including healthcare, medical device manufacturing, and the food and beverage industries. Its systems are aimed at ensuring safety and compliance with industry standards, thereby fostering a safe and productive work environment.

Celsense, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, specializing in the development of innovative magnetic resonance imaging (MRI) agents designed to non-invasively visualize and quantify biological processes at the cellular level. The company's primary offerings include Cell Sense, a MRI cell tracer for monitoring transplanted cells; Gene Sense, a DNA-encoded marker that allows cells to express their own contrast agent; and V-sense, a fluorine-based MRI tracer. Additionally, Celsense provides Voxel Tracker, which facilitates rapid visualization and quantification of MRI-labeled cells. These products are instrumental in regenerative medicine and immunotherapy, allowing for the monitoring of cellular therapeutics, inflammation, cancer metastases, and immune system responses. Founded in 2005, Celsense collaborates with various pharmaceutical and biotechnology organizations to develop applications suitable for human use.

StageMark develops and markets inflammatory diseases identification and monitoring solutions. The company's product, CB-CAPs, enables user to analyze complement products bound to various blood cell types such as erythrocytes, platelets, reticulocytes, and lymphocytes. StageMark, Inc. was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.

STARR Life Sciences Corp. specializes in the development and manufacturing of research equipment for small animal studies, aimed at advancing life sciences. Based in Oakmont, Pennsylvania, the company offers a range of products including the MouseOX Plus pulse oximeter, which measures vital parameters such as heart rate, arterial oxygen saturation, and temperature in mice and rats. Additionally, STARR Life Sciences provides the E-Mitter Telemetry System, enabling continuous monitoring of temperature, activity, and heart rate through implantable telemetry devices and accompanying software. Their product lineup also includes incage running wheels, activity cage systems, and infrared motion sensors, all designed to facilitate non-invasive observation of animal health and behavior. The company's offerings are utilized by researchers, veterinarians, and institutions within the pharmaceutical and academic sectors, reflecting a commitment to supporting medical research through innovative technology.

Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company based in Pittsburgh, Pennsylvania, specializing in supportive care for cancer survivors who experience hemorrhagic cystitis. Founded in 2005, the company develops innovative products for intravesical therapy, delivering localized treatments directly to the urinary bladder. Its primary product in clinical development is LP-10, a liposomal formulation of tacrolimus aimed at treating hemorrhagic cystitis. Additionally, Lipella focuses on other conditions such as interstitial cystitis, overactive bladder, and superficial bladder cancer, which affect a significant number of patients in the United States. The company also engages in surveillance and imaging for patients with a history of transitional cell carcinoma, alongside offering clinical supplies and research products.

Applied Computational Technologies is a software development company that specializes in applications for the life sciences, particularly in radiation treatment planning for cancer therapy. With a significant number of cancer diagnoses in the United States, a large portion of patients undergo radiation treatment, highlighting the importance of effective planning tools. The company's flagship product, ProACTive, serves as a dose calculation engine that facilitates adaptive radiotherapy, enhancing the precision and effectiveness of cancer treatment. Through its innovative software solutions, Applied Computational Technologies aims to improve patient outcomes in the challenging field of oncology.

RedPath Integrated Pathology, LLC is a reference laboratory based in Pittsburgh, Pennsylvania, that specializes in oncology diagnostics. Founded in 2004, the company provides support services to pathologists, clinicians, and patients through its innovative PathFinderTG testing platform. This platform is designed for the early and definitive diagnosis of cancer, utilizing genetic analysis to extract objective and quantitative information from small tissue biopsies, cytology samples, and fluid specimens. RedPath's approach aids in resolving diagnostic challenges, particularly in cases where cancer does not respond as expected to treatment.

Immunetrics, Inc. is a biosimulation company based in Pittsburgh, Pennsylvania, focused on developing biological models and tools for mechanistic modeling in drug discovery and development. Established in 2003, the company offers a software platform called Aegis, which supports model developers in creating disease-specific models and virtual populations. Immunetrics provides a range of modeling services, including pharmacology modeling that integrates biological pathways to predict clinical outcomes of therapeutic interventions in various medical conditions, particularly acute and chronic inflammatory diseases and autoimmune disorders. Additionally, the company offers consulting services for mechanistic and statistical modeling, as well as data analysis, enabling researchers to better understand and analyze human diseases and syndromes.

Proteopure offers protein isolation solutions for proteomic results. The company provides a universal method for isolating proteins. Its sample preparation kit uses a protein capture technology, and can specifically separate out proteins from various contaminants, including salts, nucleic acids, and detergents. Proteopure is headquartered in Pittsburgh, Pennsylvania.

Diamyd Medical develops the diabetes vaccine Diamyd®, an antigen-specific immunotherapy based on the exclusively licensed GAD-molecule. GABA constitutes alongside with the diabetes vaccine a key asset in Diamyd Medical and the Company uses its GABA in-licensed technology to develop a proprietary GABA drug product. Diamyd Medical’s shares are traded on Nasdaq Stockholm First North, ticker DMYD B.

Applied Isotope Technologies, Inc. specializes in providing measurement solutions for various sectors, including industrial, medical, and academic fields. The company develops and manufactures advanced analytical tools such as direct isotope dilution mass spectrometry (D-IDMS) and direct speciated isotope dilution mass spectrometry (D-SIDMS), which are designed for accurate elemental and molecular analyses. Its product offerings encompass isotopic spikes, reagent kits, and analytical standards specifically tailored for environmental testing, food safety, and biomarker detection. Additionally, Applied Isotope Technologies offers quality assurance certification, training, and technical support services to help laboratories implement precision measurement techniques. Founded in 2003 and based in Pittsburgh, Pennsylvania, the company plays a critical role in environmental toxin detection and other complex analytical challenges.

StageMark develops and markets inflammatory diseases identification and monitoring solutions. The company's product, CB-CAPs, enables user to analyze complement products bound to various blood cell types such as erythrocytes, platelets, reticulocytes, and lymphocytes. StageMark, Inc. was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.

Blue Belt Technologies, Inc. focuses on the development and commercialization of robotics-assisted technologies designed for orthopedic surgery and other medical specialties. The company offers the Navio surgical system, which integrates intelligent handheld instruments with a CT-free registration and patient-specific planning process. Additionally, it provides the STRIDE unicondylar knee system for treating early-stage osteoarthritis in the knee, along with software applications that assist surgeons in planning knee replacements. These applications help in localizing implant components and balancing soft tissue. Beyond product offerings, Blue Belt Technologies also delivers support services, maintenance programs, and onsite training. Founded in 2003 and headquartered in Plymouth, Minnesota, Blue Belt Technologies became a subsidiary of Smith & Nephew in January 2016.

MedSage Technologies specializes in providing software and services tailored for healthcare providers within the home medical equipment industry. The company offers a range of solutions, including management tools for obstructive sleep apnea (OSA), diabetes, and enteral services, as well as support for rental equipment and respiratory medications. Additionally, MedSage Technologies focuses on enhancing sleep lab outcomes, thereby addressing various needs in the evolving healthcare landscape.